title: Association of cytomegalovirus interstitial pneumonitis with HLA-type following allogeneic bone marrow transplantation.
abstract: Certain human leukocyte antigens may increase the risk of cytomegalovirus interstitial pneumonitis, an important complication of bone marrow transplantation. The prevalence of this pneumonitis was compared between patients possessing either HLA-B51 or HLA-B52 and patients without either antigen. The role of tumor necrosis factor-alpha in cytomegalovirus interstitial pneumonitis was also studied. Among 72 patients undergoing allogeneic bone marrow transplantation at our institution during the past 5 years, HLA-B51 or -B52 was detected in 29. Among these 29 patients, 13 (45%) developed cytomegalovirus interstitial pneumonitis, a significantly higher rate (P < 0.001) than among patients without these HLA types (4/43, 9%). In the pre-conditioning and stable phases, tumor necrosis factor-alpha levels were higher in patients with HLA-B51 or HLA-B52 than in patients without (P < 0.05; t-test). Throughout the period from pre-conditioning to around day 40, except on day 0, tumor necrosis factor-alpha levels were also significantly higher (P < 0.05 to P < 0.001) in patients developing cytomegalovirus infection than in those without it. These results suggest that HLA-B51 and HLA-B52 may be risk factors for cytomegalovirus interstitial pneumonitis after bone marrow transplantation, with an increase of tumor necrosis factor-alpha also being involved.
authors.affiliation: Second Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Takatsuka
authors.forename: Y
authors.initials: Y
authors.lastname: Takemoto
authors.forename: T
authors.initials: T
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Fujimori
authors.forename: S
authors.initials: S
authors.lastname: Tamura
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: A
authors.initials: A
authors.lastname: Kanamaru
authors.forename: E
authors.initials: E
authors.lastname: Kakisita
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003586:Cytomegalovirus Infections; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens / Q000097:blood*; D015235:HLA-B Antigens / Q000097:blood; D059949:HLA-B51 Antigen; D059950:HLA-B52 Antigen; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000276:immunology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013997:Time Factors; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014775:Virus Activation
chemical_list: D006680:HLA Antigens; D015235:HLA-B Antigens; D059949:HLA-B51 Antigen; D059950:HLA-B52 Antigen; D014409:Tumor Necrosis Factor-alpha